Annals of Oncology is a monthly peer-reviewed journal of Elsevier, founded in 1990 and indexed in the Science Citation Index Expanded with a 2025 Impact Factor of 80.4Annals of Oncology 是 Elsevier 旗下的同行评审月刊，创刊于 1990 年，被科学引文索引扩展版收录，2025 年影响因子为 80.4。
Clinical and translational research in oncology, including innovative cancer treatments and precision medicine发表肿瘤学临床与转化研究，涵盖创新癌症治疗与精准医学。
Reports on clinical trials, new therapies, and advances in the multidisciplinary management of cancer刊载临床试验、新疗法以及癌症多学科诊疗进展的报告。
Coverage of medical oncology, surgical oncology, radiation oncology, and supportive care涵盖内科肿瘤学、外科肿瘤学、放射肿瘤学以及支持治疗。
Studies on molecular oncology, biomarkers, immunotherapy, and targeted therapies研究分子肿瘤学、生物标志物、免疫治疗与靶向治疗。
Editorials, reviews, and guidelines that inform oncology practice and research发表指导肿瘤临床实践与研究的社论、综述与指南。
The journal was founded in 1990 as the official journal of the European Society for Medical Oncology该刊于 1990 年创刊，是欧洲肿瘤内科学会的官方期刊。
It is also recognized as the official journal of the Japanese Society of Medical Oncology该刊同时被认定为日本肿瘤内科学会的官方期刊。
Its impact factor has risen substantially, reflecting its position as a top-tier oncology journal其影响因子大幅提升，体现了其作为顶级肿瘤学期刊的地位。
Annals of Oncology publishes monthly and maintains a large international editorial board该刊每月出版，并拥有庞大的国际化编委会。
Editor-in-Chief is Thomas Powles, based in London, United Kingdom主编为 Thomas Powles，任职于英国伦敦。
A deputy editor and associate editors oversee specific tumor types and research areas副主编与编委负责各肿瘤类型与研究方向的稿件处理。
An international editorial board of oncology experts supports peer review and journal direction由肿瘤学专家组成的国际化编委会支持同行评审与期刊方向。
Authors may choose open access publication through Elsevier's hybrid open access option作者可通过 Elsevier 的混合型开放获取选项发表开放获取论文。